Excellence in Single Domain Biotherapeutics
Isogenica develops therapeutic VHH: highly versatile small format antibodies which we use to construct next generation biotherapeutics for the treatment of cancer, inflammation and other serious diseases.
Our VHH can be assembled to create bispecific and multi-specific biotherapeutics, or used to achieve targeted drug delivery as components of ADCs and cell and gene therapies including CAR-Ts.
News & Events
📣 Synthetic libraries are our forte and here’s why…
This edition we’re talking synthetic libraries: read on to see how we can save up to 8 months on immunisation alone compared with traditional approaches. Since November we’ve seen Dave attend Genesis in London, Ben go to PEGS, Barcelona, and Marion off to CAR-T, London. March will see our MRC iCASE PhD student, Natasha Spena continue her project at the University of Leicester. We’re proud to announce a new partnership with Arvinas, and finally, we ask: was our Director of Business Development, Dave Mead, correct about his biopharma predictions for 2023? And look to his predictions for 2023.
CIS display, a DNA-based in vitro selection technology for therapeutic peptides
CIS display is a DNA-based in vitro display technology that enables the display and selection of peptides and proteins from extremely large libraries…
CAR-T London Spring 2023
Back in February 2023 our Director of Discovery, Marion Cubitt attended the 6th Annual CAR-TCR summit.
Stay up to date with our latest news and posts on LinkedIn
Isogenica’s partnerships with global biopharmaceutical companies have resulted in a deep pipeline including one clinical Phase II asset and eleven partnered pre-clinical and discovery programs.
Isogenica works with partners through collaborative research and commercial licenses to further develop proprietary LlamdA® VHH or to discover novel LlamdA® VHH as direct therapeutics and targeting agents.
Isogenica’s LlamdA® VHH synthetic libraries are displayed in phage or in the company’s proprietary CIS Display technology.
These are combined to provide a powerful discovery engine for single domain biotherapeutics.
Careers at Isogenica
A career at Isogenica provides an opportunity to lead, execute or support the commercial development of next generation biotherapeutics.